Open Access<p>Telemedicine Follow-Up for Intravitreal Bevacizumab Injection in the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) Cohort</p>
Author(s) -
Marco H. Ji,
Natalia F. Callaway,
Margaret A. Greven,
Daniel Vail,
Darius M. Moshfeghi
Publication year - 2020
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s250361
Subject(s) - retinopathy of prematurity , medicine , telemedicine , bevacizumab , ophthalmology , cohort , pediatrics , optometry , surgery , pregnancy , gestational age , chemotherapy , health care , genetics , economic growth , economics , biology
Telemedicine has emerged as a potential solution to face the disproportion between infants that need to be screened for retinopathy of prematurity (ROP) and the lack of ophthalmologists. We evaluated its utility in the follow-up after off-label intravitreal injection of bevacizumab. None of the treated infants ended up with bad anatomic outcome. Telemedicine is an alternative safe method to monitor patients after treatment.